118811-03-3

Basic information

• Product Name: 2-(2-HYDROXY-ETHYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: BOC-2-(2-PIPERIDYL)ETHANOL;2-(2-HYDROXYETHYL)-1-BOC-PIPERIDINE;2-(2-HYDROXY-ETHYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-BOC-2-(2-HYDROXY-ETHYL)-PIPERIDINE;(+/-)-N-BOC-PIPERIDINE-2-ETHANOL;N-BOC-2-HYDROXYETHYLPIPERIDINE;N-BOC-2-(2-HYDROXYETHYL)PIPERIDINE;N-BOC-2-PIPERIDIN-2-YL-ETHANOL
• CAS NO: 118811-03-3
• Molecular Formula: C₁₂H₂₃NO₃
• Molecular Weight: 229.32
• Product Categories: pharmacetical
• Mol File: 118811-03-3.mol

Chemical Properties

• Boiling Point: 100-110 °C/0.3 mmHg
• Flash Point: 110 °C
• Appearance: /
• Density: 1.032 g/mL at 25 °C
• Vapor Pressure: 6.34E-06mmHg at 25°C
• Refractive Index: n20/D 1.472
• PKA: 15.15±0.10(Predicted)
• CAS DataBase Reference: 2-(2-HYDROXY-ETHYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-HYDROXY-ETHYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(118811-03-3)
• EPA Substance Registry System: 2-(2-HYDROXY-ETHYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(118811-03-3)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 24/25-45
• RIDADR: UN 2810 6.1/PG 3
• WGK Germany: 3
• Hazardous Substances Data: 118811-03-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(2-HYDROXY-ETHYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a reactant for the synthesis of various pharmaceutical agents due to its chemical reactivity and structural diversity. It plays a crucial role in the development of new drugs and therapeutic compounds.
Used in the Synthesis of Vasopressin 1b Receptor Antagonists:
In the pharmaceutical industry, 2-(2-HYDROXY-ETHYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a reactant for the synthesis of vasopressin 1b receptor antagonists. These antagonists are important for the treatment of various conditions, such as heart failure and kidney diseases, by blocking the vasopressin 1b receptor and modulating water balance in the body.
Used in the Synthesis of CXCR4 Antagonists as Anti-HIV Agents:
2-(2-HYDROXY-ETHYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is also utilized in the synthesis of CXCR4 antagonists, which are essential in the development of anti-HIV drugs. CXCR4 antagonists work by blocking the CXCR4 receptor, which is a co-receptor for HIV entry into the host cells, thus preventing the virus from infecting the cells and spreading the infection.
Used in the Synthesis of Coumarin-based Inhibitors of Inducible Nitric Oxide Synthase:
2-(2-HYDROXY-ETHYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is employed in the synthesis of coumarin-based inhibitors of inducible nitric oxide synthase (iNOS). These inhibitors are significant in the treatment of various inflammatory and cardiovascular diseases by regulating the production of nitric oxide, a molecule involved in the immune response and blood vessel dilation.
Used in the Synthesis of Selective Thrombin Inhibitors:
The compound is also used as a reactant for the synthesis of selective thrombin inhibitors. These inhibitors are vital in the treatment of thrombotic disorders, such as deep vein thrombosis and pulmonary embolism, by selectively targeting thrombin, a key enzyme in the blood clotting process.
Used in the Synthesis of Amino Alcohols via N-directed Hydroboration:
2-(2-HYDROXY-ETHYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is utilized in the synthesis of amino alcohols through N-directed hydroboration. Amino alcohols are essential building blocks in the development of various pharmaceutical agents, including antibiotics, antifungals, and anticancer drugs.
Used in the Enantioselective Synthesis of Sedamine and Allosedamine:
2-(2-HYDROXY-ETHYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is also employed in the enantioselective synthesis of sedamine and allosedamine, which are important alkaloid compounds with potential applications in the pharmaceutical industry. Enantioselective synthesis allows for the production of specific enantiomers of these compounds, which can have different biological activities and therapeutic properties.

InChI:InChI=1/C11H22N2O3/c1-11(2,3)16-10(15)13-6-5-12-8-9(13)4-7-14/h9,12,14H,4-8H2,1-3H3

Upstream product

• 1484-84-0 2(RS)-(2-hydroxyethyl)piperidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 3040-44-6 1-piperidinoethanol 
• 183859-36-1 methyl (+/-)-N-(tert-butyloxycarbonyl)piperidin-2-ylacetate 
• 41840-28-2 S-tert-butoxycarbonyl-4,6-dimethyl-2-mercaptopyrimidine 
• 98303-20-9 1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid 
• 133633-94-0 (±)-hexahydro-3H-pyrido[1,2-c][1,2,3]oxathiazine 1,1-dioxide 

Downstream Products

• 170491-61-9 2-(2-oxoethyl)-1-piperidinecarboxylic acid tert-butyl ester 
• 199861-90-0 2-{2-[7-chloro-3-(3.5-dimethylphenyl)-6-iodo-2-oxo-1,2-dihydroquinolin-4-yloxy]-ethyl}-piperidine-1-carboxylic acid tert-butyl ester 
• 199861-72-8 2-{2-[7-chloro-3-(3,5-dimethylphenyl)-6-nitro-2-oxo-1,2-dihydroquinolin-4-yloxy]-ethyl}-piperidine-1-carboxylic acid tert-butyl ester 
• 199942-79-5 2-{2-[3-(3-bromophenyl)-7-chloro-6-nitro-2-oxo-1,2-dihydroquinolin-4-yloxy]-ethyl}-piperidine-1-carboxylic acid tert-butyl ester 
• 199861-86-4 2-{2-[6-allyl-7-chloro-3-(3,5-dimethylphenyl)-2-oxo-1,2-dihydroquinolin-4-yloxy]-ethyl}-piperidine-1-carboxylic acid tert-butyl ester 
• 190846-68-5 N-t-butyloxycarbonyl-2(RS)-[2-(4-cyanophenoxy)ethyl]piperidine 
• 199942-74-0 (S)-2-(2-hydroxy-ethyl)-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Formal synthesis of (±)-sedamine through gold(I)-catalyzed intramolecular dehydrative amination of sulfamate esters tethered to allylic alcohols

A concise formal synthesis of (±)-sedamine has been accomplished. The synthesis is straightforward and demonstrates high efficiency. Key steps involve gold(I)-catalyzed cyclization of sulfamate esters tethered to allylic alcohols, sulfamate N-alkylation, and ring-closing metathesis.

A general method for making bicyclic compounds with nitrogen at a bridgehead-application to the halichlorine spiro subunit

N-Protected β-amino aldehydes having the nitrogen in a ring are easily converted into Morita-Baylis-Hillman adducts; O-acetylation and N-deprotection result in spontaneous cyclization to bicyclic structures having nitrogen at a bridgehead. The Royal Socie

Synthesis of Azocanes from Piperidines via an Azetidinium Intermediate

α-Trifluoromethyl azocanes are accessible from 2-(trifluoropropan-2-ol) piperidines by metal-free ring-expansion involving a bicyclic azetidinium intermediate. The opening of the azetidinium intermediate was achieved by various nucleophiles (amines, alcoholates, carboxylates, phosphonates, halides and pseudo-halides) with an excellent regio- diastereo- and enantioselectivity and in good yields. The relative configuration of the piperidines and azocanes were assigned and the deprotected azocanes offer opportunities for further derivatization.

The phenothiazine compound and its preparation method and application

The invention relates to a phenothiazine compound and a preparation method thereof. The invention further relates the application of the phenothiazine compound in anti-cancer drug preparation and anti-cancer drugs using the compound as the effective component. The phenothiazine compound has the advantages that the compound with broad-spectrum anti-cancer effect is obtained by modifying phenothiazine ternary interlink parent nucleuses, synthesizing method is simple, and high yield is achieved; the phenothiazine compound has certain restraining effect on human breast cancer cells line MCF-7 and human hepatoma cell line Hep-G2, and a new thought is provided to new drugs satisfying clinic requirements.

Synthesis and SAR evaluation of novel thioridazine derivatives active against drug-resistant tuberculosis

The neuroleptic drug thioridazine has been recently repositioned as possible anti-tubercular drug. Thioridazine showed anti-tubercular activity against drug resistant mycobacteria but it is endowed with adverse side effects. A small library of thioridazine derivatives has been designed through the replacement of the piperidine and phenothiazine moieties, with the aim to improve the anti-tubercular activity and to reduce the cytotoxic effects. Among the resulting compounds, the indole derivative 12e showed an antimycobacterial activity significantly better than thioridazine and a cytotoxicity 15-fold lower.

Catalytic Oxygenative Allylic Transposition of Alkenes into Enones with an Azaadamantane-Type Oxoammonium Salt Catalyst

The first catalytic oxygenative allylic transposition of unactivated alkenes into enones has been developed using an oxoammonium salt as the catalyst. This reaction converts various tri- and trans-disubstituted alkenes into their corresponding enones with transposition of their double bonds at ambient temperature in good yields. The use of a less-hindered azaadamantane-type oxoammonium salt as the catalyst and a combination of two distinct stoichiometric oxidants, namely, iodobenzene diacetate and magnesium monoperoxyphthalate hexahydrate (MMPP?6 H2O) are essential to facilitate the enone formation efficiently.

Compounds and methods for treating tumors

The present invention relates to pharmaceutical compositions and methods for controlling tumor growth in cancer patients. These compounds and pharmaceutical compositions modulate the P-glycoprotein multidrug transporter system and inhibit the activated PI3K/Akt/mTOR/p70S6K signaling pathway. The compounds and pharmaceutical compounds of the present invention are particularly useful for treating metastatic and drug-resistant tumors.

USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS

The present application provides methods of using the aminoindane compounds of formula (I) or (II) in treating an overactive bladder or interstitial cystitis by administering one or more of the compounds to a patient.

Aminoindane Compounds and Use Thereof in Treating Pain

The present application provides novel aminoindane compounds and methods for preparing and using these compounds. These compounds are useful in treating pain and/or itch in patients by administering one or more of the compounds to a patient. The methods include administering a compound of formula (I) or (II) and a TRPV 1 receptor activator. In one embodiment, the TRPV 1 receptor activator is lidocaine.

Novel N-substituted benzimidazole CXCR4 antagonists as potential anti-HIV agents

The lead optimization of a series of N-substituted benzimidazole CXCR4 antagonists is described. Side chain modifications and stereochemical optimization led to substantial improvements in potency and protein shift to afford compounds with low nanomolar a